Warhound Raises $200M to Engineer Genetically Modified Military Dogs
What started as a casual conversation between two Silicon Valley entrepreneurs has evolved into a $1.2 billion company. Warhound, emerging from stealth today, aims to revolutionize the supply of working dogs for U.S. military and law enforcement agencies — using genetic engineering, cloning, and next-generation defense equipment.
The company was conceived by Ben Lamm, co-founder of Colossal Biosciences — known for its ambitious de-extinction projects including the dodo and the mammoth — and Palmer Luckey, the young millionaire behind Anduril Industries, a defense technology giant that has become one of the Pentagon's largest contractors. Notably, Luckey does not hold equity in Warhound; he acts only as a partner, with Colossal owning the equity and licensing its genetic technology.
The problem Warhound wants to solve
America's dependence on foreign working dogs is a national security issue few discuss publicly. According to Warhound's own data, more than 80% of U.S. military working dogs are acquired from Europe. This creates a strategic vulnerability: after a rigorous acquisition and training pipeline lasting approximately three years, less than half of the acquired dogs are deemed fit for service. That means the U.S. needs to purchase and train roughly 200 dogs to field only 100 operational animals.
"There's a shortage of dogs," Lamm told TechCrunch. "A lot of the top dogs have already been picked over, resulting in a genetic bottleneck and increasing inbreeding with international dogs."
Ben Lamm, of Colossal Biosciences
The solution proposed by Warhound is vertically integrated: precision genetic engineering, secure biobanking, controlled cloning, specialized training, and — on the finished products — integration with protective equipment developed by Anduril.
The technology behind the "warhounds"
The genetic core of the project resides in Colossal Biosciences. The Warhound scientific team works with cell lines from two of the world's most prestigious working dog breeds: the Belgian Malinois and the German Shepherd. From these cells, researchers edit approximately 20 sites across 14 genes, using advanced genomics data to preserve and potentially enhance traits associated with combat mission performance — including agility, endurance, smell, and threat processing capability.
This is not about creating science fiction monsters. According to Lamm, the approach is to "make the dog safer, make it healthier, make it perform better." The goal is to produce animals that are more robust, with fewer genetic disorders common in working breeds, and with potentially enhanced sensory capabilities for detecting explosives or chemical threats.
Colossal already uses artificial intelligence to accelerate animal gene identification and cloning — technology previously developed for its de-extinction projects. Viagen, a subsidiary also belonging to Colossal, has a notable success rate in cloning, currently applied to endangered species preservation.
Anduril's contribution: "on-top" hardware
While Colossal handles the biology, Anduril Industries focuses on what Lamm describes as improvements "on the dog, not in the dog." Luckey's subsidiary will provide advanced protective equipment — from ballistic vests adapted for canines to augmented reality goggles to enhance situational awareness for both dogs and their handlers.
These devices would allow K-9 teams to operate with real-time tactical information, coordinated by Anduril software already used in Pentagon surveillance and detection systems. The idea is that the dog and handler operate as an integrated combat system, with technology functioning as an amplifier of the animal's natural capabilities.
The investment: who is betting on warhounds?
Warhound's seed round totals $200 million, with contributions from some of the most important names in venture capital and the U.S. government's investment fund. In-Q-Tel — the CIA's investment arm — participates in the round, signaling the intelligence community's confidence in this technology. Sequoia Capital, a historic investor in companies like Google, Airbnb, and Stripe, is also backing the project, along with 8VC, Vincent Gray's venture capital fund.
The company's $1.2 billion valuation positions Warhound as one of the most valuable defense startups launched recently — a figure that reflects not only market potential but also the strategic convergence between biotechnology and defense that has defined the Silicon Valley investment cycle.
What to expect in the next two years
Warhound expects its first group of dogs to be born in early 2027, with the goal of entering operational service within the next two years. The company operates under the guidance of the American Humane Society, which will certify its training programs, and plans for retired dogs to participate in the military working dog reunification program, placing them in adoptive homes.
The price the company will charge for the dogs has not yet been disclosed. Lamm said Warhound has already conducted briefings with several government groups and is working to secure regulatory approvals before any sales. The target audience includes the Department of Defense, military forces, police departments, and emergency response teams.
When asked about government approval for creating genetically modified animals for military purposes, Lamm emphasized that the company has been transparent with regulators: "We've briefed many government groups on the business," he said. The dogs will be trained and managed exactly the same way as any existing military working dog — and the genetic and hardware improvements aim, according to the founders, to reduce risk for both animals and their handlers.
The question is whether this technology could one day be adapted for other applications — and what happens when the boundary between animal and machine becomes increasingly indistinguishable.
Sources: Fortune, TechCrunch, Wired
✓ Independent sources cross-checked and verified before publishing
